The American Society of Regional Anesthesia and Pain Medicine (ASRA) convened its
Fourth Consensus Conference on Regional Anesthesia and Anticoagulation in conjunction …

The recommendations listed in this document are, whenever possible, evidence based. An
extensive evidence review was conducted, focusing on 2006 through October 2012 and …

The recommendations listed in this document are, whenever possible, evidence based. An
extensive evidence review was conducted, focusing on 2006 through October 2012 and …

The Vitamin K antagonist warfarin was the only oral anticoagulant available for decades for
the treatment of thrombosis and prevention of thromboembolism until Direct Oral …

Background: Over the last ten years, a new class of drugs, known as the direct-acting oral
anticoagulants (DOACs), have emerged at the forefront of anticoagulation therapy. Like the …

Venous thromboembolism (VTE) in acute medically ill patients is a leading cause of in-
hospital morbidity and mortality. A majority of these VTE events occur post-discharge, and …

Patients requiring neurosurgical procedures, including elective and emergent surgery, are
often receiving an anticoagulant for a non-neurosurgical indication, such as atrial fibrillation …

Direct oral anticoagulants (DOACs) are first-line drugs used for the treatment of venous
thromboembolism and prevention of stroke in patients with atrial fibrillation. These drugs do …

Thrombosis is a leading cause of death in cardiovascular diseases such as myocardial
infarction (MI), unstable angina and acute coronary syndrome (ACS) in the industrialized …

Venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary
embolism (PE), remains a preventable cause of morbidity and mortality in hospitalized …